-
High maternal viral load is the most important factor causing maternally transmitted hepatitis B virus (HBV) infection and is significantly correlated with e antigen (HBeAg) positivity, according to a prospective study from Taiwan.
19 March 2013 | Medscape (requires registration)
-
New analysis from Frost & Sullivan, Analysis of the European Hepatitis B and C Diagnostics Market, estimates revenues of the hepatitis B diagnostics to grow from $165.9 million in 2012 to $260.2 million in 2019 and hepatitis C diagnostics market to grow from $3,140.8 million in 2012 to $4,940.9 million in 2019, respectively.
13 March 2013 | PR Newswire (press release)
-
The Safe Injection Practices Coalition, a group of healthcare-related organizations including the CDC indicated since 2001, more than 150,000 patients in the U.S. were told they may have been exposed to hepatitis B, hepatitis C, or human immunodeficiency virus because providers followed unsafe injection procedures.
12 March 2013 | UPI.com
-
Single injection induces multi-log repression of viral RNA, proteins, and viral DNA; Long duration of effect lasting over 30 days; Regulatory submissions planned for Q2 2013.
27 February 2013 | Arrowhead Research Corp press release
-
U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B vaccine pending additional data to evaluate its safety, potentially delaying the U.S. market entry of the company's first promising product.
26 February 2013 | Reuters
-
Key findings in the report suggest that alcohol consumption, viral hepatitis B and C and metabolic syndromes related to overweight and obesity are the leading causes of cirrhosis and primary liver cancer in Europe.
22 February 2013 | Eurekalert Inf Dis
-
Approximately one-third of all hepatitis B and C cases in Pakistan could be prevented by interventions directed towards a few modifiable risk factors, according to a recent study.
14 February 2013 | Vaccine News Daily (blog)
-
The website aims to help people better understand how liver cancer is diagnosed and how it can be treated or prevented. In addition, wwwLiverCancerConnect.org includes a Drug Watch of potential new liver cancer therapies, an expanding directory of liver cancer specialists, and a clinical trials listing.
07 February 2013 | Hepatitis B Foundation
-
NICE is currently developing a new clinical guideline on the diagnosis and management of chronic hepatitis B in children, young people and adults. Draft recommendations have been published on the NICE website today (17 January) for public consultation.
17 January 2013 | NICE press release
-
New guidance published today (12 December) by healthcare guidance body NICE highlights the need to tackle ignorance about the risk factors and causes of hepatitis B and C, and misconceptions about its treatment if barriers to effective testing of those at increased risk of infection are to be overcome.
12 December 2012 | NICE
Get set for HIV treatmentA tool to help you decide whether you are ready to start taking HIV treatment.
HIV, GPs & other primary careThis booklet explains the services GPs offer, how this fits with HIV specialist care, and how to make the most of primary care services.
Treatment as prevention – free webinar 20 March 2013As
part of its European HIV prevention work, NAM is collaborating...
Microbicides research – free webinar 22 February 2013As
part of its European HIV prevention work, NAM is collaborating...
HIV treatment update – Winter 2013 21 February 2013The new edition of HIV treatment update (HTU) is on...